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Abstract
Non-selective beta-blockers are the mainstay of medical 
therapy for portal hypertension in liver cirrhosis. 
Inhibitors of phosphodiesterase-5 (PDE-5-inhibitors) 
reduce portal pressure in the acute setting by > 10% 
which may suggest a long-term beneficial effect. 
Currently, there is no available data on long-term 
treatment of portal hypertension with PDE-5-inhibitors. 
This case of a patient with liver cirrhosis secondary to 
autoimmune liver disease with episodes of bleeding 
from esophageal varices is the first documented case 
in which a treatment with a PDE-5-inhibitor for eight 
years was monitored. In the acute setting, the PDE-5-
inhibitor Vardenafil lowered portal pressure by 13%. 
The portal blood flow increased by 28% based on 
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Doppler sonography and by 16% using MRI technique. 
As maintenance medication the PDE-5-inhibitor Tadalafil 
was used for eight consecutive years with comparable 
effects on portal pressure and portal blood flow. There 
were no recurrence of bleeding and no formation of 
new varices. Influencing the NO-pathway by the use of 
PDE-5 inhibitors may have long-term beneficial effects 
in compensated cirrhosis.
Key words: Portal hypertension; Phosphodiesterase-5; 
Liver hemodynamics; Doppler sonography; Magnetic 
resonance imaging; Liver cirrhosis
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Non-selective beta-blockers are the mainstay 
of medical therapy for portal hypertension in liver 
cirrhosis. Inhibitors of phosphodiesterase-5 (PDE-5) 
reduce portal pressure in the acute setting by > 10%. 
This is the first report of a patient with liver cirrhosis 
showing that in long-term treatment with a PDE-5-
inhibitor the positive effect on liver hemodynamics is 
maintained thus preventing further variceal bleeding.
Deibert P, Lazaro A, Stankovic Z, Schaffner D, Rössle M, Kreisel 
W. Beneficial long term effect of a phosphodiesterase-5-inhibitor 
in cirrhotic portal hypertension: A case report with 8 years follow-




Portal hypertension in liver cirrhosis is caused by 
several factors[1-3]. Structural changes (i.e., regenerative 
nodules and fibrosis) lead to an intrahepatic outflow 
obstruction which is aggravated by an increased portal 
blood flow (at least in early stages of cirrhosis) as a 
consequence of excessive extrahepatic nitric oxide (NO) 
production. About a quarter of the portal pressure is due 
to a functional intrahepatic component: the imbalance 
between constricting and dilating factors within the 
sinusoids and the dysregulation of the nitric oxide - 
cyclic guanosine monophosphate (NO-cGMP) system 
lead to an overactivity of stellate cells/myofibroblasts 
and contraction of sinusoids. Phosphodiesterase-5-
inhibitors (PDE-5-inhibitors) inhibit the conversion of 
cGMP to 5’-GMP[2] thus, increasing the level of cGMP, 
the second messenger, which may lead to dilation of 
sinusoids. There are conflicting data from preclinical 
and clinical studies whether or not PDE-5-Inhibitors 
lower elevated portal pressure in cirrhosis[4-6]. However, 
a recent proof-of-concept study showed that the long-
acting PDE-5-inhibitor Udenafil lowered portal pressure 
at doses of 75-100 mg by approximately 20% in the 
acute testing[7]. 
A decrease of hepatovenous pressure gradient 
(HVPG) by ≥ 20% from baseline or to a value of ≤ 
12 mm Hg after an application of non-selective beta-
blockers for more than two weeks is accepted as 
a good predictor of beneficial clinical response[8-10]. 
Meanwhile, several studies demonstrated that a 
decrease of HVPG by ≥ 10% in the acute setting 
after intravenous administration of propranolol (0.15 
mg/kg) is an adequate predictor of a clinical response 
as well[11-13]. Therefore, it may be surmised that a 
decrease of HVPG by ≥ 10% in the acute setting after 
application of a PDE-5-inhibitor may be an indicator of 
a long-term beneficial effect in liver cirrhosis with portal 
hypertension. 
In this case report of a patient with liver cirrhosis 
who had multiple episodes of bleeding esophageal 
varices we aimed to answer the following questions: 
(1) Are the decrease of portal pressure and increase of 
portal venous blood flow induced by a PDE-5-inhibitor 
long-lasting? (2) Does the long-term use of a PDE-5-
inhibitor have a beneficial clinical effect of reducing the 
risk of bleeding from esophageal varices? And (3) Do 
we see any compound-specific adverse effects in the 
long-term?
CASE REPORT
In February 2009 a 53-year-old female patient was 
admitted to the University Hospital in Freiburg, Germany 
for further evaluation. The patient was initially dia-
gnosed with autoimmune hepatitis/primary biliary 
cholangitis (AIH/PBC) overlap syndrome (positive for 
anti-nuclear antibodies, antibodies to smooth muscle 
cells, antibodies to pyruvate decarboxylase E2 subunit, 
and to soluble liver antigen) in 1989. Since histology 
and clinical chemistry showed that the AIH component 
was predominant without cholestasis, the prescribed 
therapy was a combination of corticosteroids and 
azathioprine. 
In 2006 the patient was previously admitted in the 
Hospital of Norden, Germany with the first episode of 
acute variceal bleeding with hemodynamic instability. 
Banding of varices was performed. Sonography of 
the abdominal organs showed signs of liver cirrhosis 
including enlarged spleen. No other abnormalities were 
found. Within the following 3 years she bled three 
times per year from these varices. In 2008 she had 
two episodes of bleeding from rectal varices which 
were treated with rubber band ligation. Medical therapy 
of portal hypertension with propranolol was initiated 
but had to be stopped even at the low dose of 20 
mg twice daily due to intolerable cardiovascular side 
effects (i.e., bradycardia and hypotension). The patient 
was regularly monitored in the liver transplant center 
of the University Hospital in Hannover (Medizinische 
Hochschule Hannover). She was waitlisted for liver 
transplantation and the implantation of TIPS was 
scheduled. She was referred to our hepatological unit in 
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order to check whether the application of an inhibitor of 
the enzyme phosphodiesterase-5 could be an option to 
lower portal pressure and reduce the risk for bleeding 
from esophageal varices.
The patient was in a good clinical condition upon 
admission. The physical examination findings were 
normal except for the palpable liver and minor bila-
teral varicose veins of the lower extremities. Exa-
mination of heart and lungs was unremarkable. No 
bipedal edema was present. There were no signs of 
hepatic encephalopathy. Blood pressure was 154/86 
mmHg and the heart rate was 78/min. ECG and 
echocardiography findings were normal except for 
a slight tricuspid valve insufficiency. Systolic pulmo-
nary artery pressure was not increased (26 mmHg). 
Laboratory results showed no pathological values 
except a slight increase in total bilirubin (1.6 mg/dL) 
and thrombocytopenia of 105.000/µL, establishing the 
case as Child A cirrhosis (i.e., normal bilirubin, normal 
serum albumin, normal INR, no ascites, no hepatic 
encephalopathy). In esophago-gastro-duodenoscopy 
scarring transformation of two ligated varices was 
observed. Three small varices of grade 1-2 were 
visible. At this point, the daily medication consisted of 
azathioprine 75 mg, prednisolone 5 mg, pantoprazole 
20 mg, and calcium 500 mg. 
To test the effect of a PDE-5-inhibitor on portal 
hemodynamics in February 2009 10 mg of Vardenafil 
were administered orally. Wedged hepatic vein pressure 
(WHVP) and free hepatic vein pressure (FHVP) were 
measured in triplicate before and one hour after the 
drug administration. The HVPG, defined as WHVP - 
FHVP, decreased by 14% from 10.5 to 9.0 mmHg. 
Duplex sonography showed an increase in portal flow 
by 28% (0.97 L/min to 1.24 L/min) 60 min after drug 
intake. Systemic blood pressure changed from 130/87 
to 121/75 mmHg one hour after drug administration, 
while heart rate changed from 65 to 61/min. Portal flow 
monitored by flow-sensitive 3D magnetic resonance 
imaging increased by 16 % (0.85 L/min to 0.99 L/min). 
Maximal flow velocity remained constant, at 24 cm/s in 
duplex sonography and 17 cm/s in 3D MRI. No relevant 
effect was observed on systemic blood pressure. 
Visualization of the portal venous system by MRI (Figure 
1) confirmed the duplex sonographic findings of a 
prograde blood flow in the portal vein and the two main 
intrahepatic branches and a recanalized umbilical vein 
originating from the left main branch of the portal vein.
We discussed an experimental therapeutic approach 
of the application of a PDE-5-inhibitor with the patient. 
The patient was informed that this was an off-label 
use and gave written informed consent. After having 
verified that the PDE-5-inhibitor Vardenafil decreased 
HVPG and that it led to an increase of portal venous 
blood flow confirmed by two independent methods 
we decided to start a long-term therapy with 5 mg 
Tadalafil/day, as this PDE-5-inhibitor has a longer half-
life than Vardenafil. In June 2009 an HVPG one hour 
after oral administration of 5 mg Tadalafil of 10.5 mm 
Hg was measured. Portal venous blood flow remained 
elevated at 1.21 L/min. Systemic blood pressure 
showed no clinically relevant changes (124/79 mmHg, 
heart rate 88/min to 127/77 mmHg, heart rate 64/min) 
in the acute setting. The next evaluation was performed 
in October 2009 wherein after 10 mg Tadalafil the 
HVPG decreased by 15% from 12.0 to 10.0 mm Hg. 
Portal venous blood flow remained markedly elevated 
(1.28 L/min in Duplex sonography and 0.99 L/min as 
measured by MRI). In March 2010 HVPG was 10.5 mm 
Hg, while portal venous blood flow remained about 
30% higher than the initial reading as verified by the 
two methods. Notably, the flow in the umbilical vein 
was not influenced by the PDE-5-inhibitor. The results 
of the measurements are shown in Table 1. No relevant 
changes in heart rate or blood pressure occurred. 
In April 2010 a second-grade esophageal varix was 
injected with acryl-glue prophylactically. In March 2011 
the last measurement of portal blood flow using duplex 
sonography and the MRI method was performed. It 
showed that the portal venous blood flow remained 
constant at a level above than at the start of treatment. 
Further invasive portal pressure measurements were 
not performed. 
The clinical course of the patient remained stable. 
The portal venous blood flow determined by duplex 
sonography was constant within the range of 1.2 and 
1.4 L/min. Endoscopic monitoring every six months 
showed scarring in the distal esophagus and with 
no signs of new esophageal varices. The varices 
remained closed by thrombosis. Two episodes of upper 
gastrointestinal bleeding occurred in 02/2016 and 
04/2016. Upper endoscopy excluded bleeding from 
varices or portal hypertensive gastropathy. The bleeding 
from the small visible erosions in the duodenum was 
attributed to NSAID use which the patient had taken 
due to headache. After administration of a proton pump 
inhibitor no further bleeding occurred. In 12/2016 
portal flow was quantified to be 1.06 L/min. However, 














Figure 1  Time-resolved 3D MRI image shows prograde blood flow in the 
extrahepatic portal venous system and a recanalization of the umbilical 
vein with flow over the left branch of the intrahepatic portal vein. PV: 
Portal vein; smv: Superior mesenteric vein.
Deibert  P et  al. PDE-5-inhibitors in portal hypertension
441 January 21, 2018|Volume 24|Issue 3|WJG|www.wjgnet.com
effects to systemic hemodynamics were detected.
For several years the question whether or not 
an inhibition of the enzyme PDE-5 lowers portal hy-
pertension in patients with liver cirrhosis remained 
unanswered. The idea to use a PDE-5-inhibitor in portal 
hypertension has mainly been derived from theoretical 
consideration based on known or assumed biochemi-
cal mechanisms involved in portal hypertension[16,17]. 
Meanwhile, the results of a proof-of-concept study were 
published showing that the long-acting PDE-5-inhibitor 
Udenafil lowers portal pressure in liver cirrhosis in a 
dose dependent-manner in the acute setting[8]. The 
authors tried to explain the conflicting data obtained 
from other working groups and suggested that the 
effect of a PDE-5-inhibitor is dose-dependent and that 
the most pronounced effect could be seen in early to 
middle stages of liver cirrhosis, when the regulation of 
the sinusoidal tonus could still be influenced. However, 
the potential for a beneficial or detrimental effect of 
PDE-5 inhibitors may depend on the stage of liver 
disease and the extension of portal collaterals as it has 
been postulated for nitrates[18].
According to recently published articles, a decrease 
of HVPG by > 10% after acute administration of 
propranolol might be sufficient to predict a beneficial 
clinical effect on rate of rebleeding[11-13]. In this case it 
was shown that using the short acting PDE-5-inhibitor 
Vardenafil and the long-acting PDE-5-inhibitor Tadalafil 
the portal pressure decreased by 14% and by 15%, 
respectively. These data are consistent with other 
published reports[4,7]. It was therefore interesting to 
monitor the effect of the PDE-5-inhibitor on clinical 
outcome measures in this patient. It was possible to 
observe the effect of Tadalafil on HVPG for one year. 
If a PDE-5-inhibitor lowers portal pressure this may 
be achieved by dilation of sinusoids which leads to a 
concomitant increase of portal venous blood flow[4]. 
this was measured with a different sonographic device. 
The next sonographic examination in 09/2017 with the 
original device revealed a constant portal blood flow of 
1.29 L/min.
Figure 2 shows the distal aspect of the esophagus 
with visible scars caused by sclerosing and banding, 
with the old varices remained thrombosed. Figure 3 
shows an abdominal computer tomographic angio-
graphy. The portal vein (solid arrow) was perfused 
in a prograde direction, the diameter was enlarged. 
There were collateral veins at the splenic hilus and an 
enlarged left ovarian vein (dashed arrows). 
The patient continued the daily intake of 5 mg Tadalafil. 
Other medications consisted of 75 mg Azathioprine 
per day and 2.5 mg Prednisone per day. Because of 
the stable clinical condition the patient is no longer 
on the list of liver transplant candidates. During the 
time of follow-up the number of varicose veins of the 
lower extremities increased and a local therapy was 
suggested.
DISCUSSION
This case report describes a consistent beneficial 
effect of a PDE-5-inhibitor in a patient with portal 
hypertension due to AIH/PBC overlap syndrome who 
had bled from esophageal varices. HVPG decreased 
by 14% at the initial hemodynamic test and by 15% 
a few months later. Portal venous flow increased by 
28% as measured by Doppler ultrasound and by 16% 
as measured by four-dimensional flow MRI[14,15]. These 
measurements persisted for more than eight years 
and were accompanied by a beneficial clinical effect. 
Since the start of a therapy with 5 mg Tadalafil per day 
no further esophageal variceal bleeding occurred for 
eight years. Compound-specific adverse effects were 
not observed. In particular, no clinically significant side 
Table 1  Measurements of hepatic hemodynamic parameters
Time Flow portal vein (L/min) Flow umbi-lical 
vein (L/min)
HVPG (mmHg) Blood pressure (mmHg) Heart rate (beats/min)
Duplex MRI MRI
Start 02/2009 0.97 0.85 0.53 10.5 130/87 69
1 h post Vardenafil 10 mg 02/2009 1.24 0.99 0.56 9.0 (-14%) 121/75 61
4 mo Tadalafil 5 mg/d 06/2009 1.21 0.56 10.5 127/77 64
Without PDE-5-I 10/2009 12
1h post Tadalafil 5 mg 10/2009 1.28 0.99 0.53 10.0 (-15%) 110/70 84
11 mo Tadalafil 5 mg/d 03/2010 1.32 1.33 10.5 120/80 70
20 mo Tadalafil 5 mg/d 10/2010 1.34 115/75 77
26 mo Tadalafil 5 mg/d 04/2011 1.26 1,34 125/80 72
32 mo Tadalafil 5 mg/d 10/2011 1.25 117/70 66
46 mo Tadalafil 5 mg/d 12/2012 1.20 131/85 70
53 mo Tadalafil 5 mg/d 07/2013 1.20 110/70 68
60 mo Tadalafil 5 mg/d 02/2014 1.20 115/75 78
70 mo Tadalafil 5 mg/d 12/2014 1.20 110/70 70
81 mo Tadalafil 5 mg/d 11/2015 1.40 135/85 65
84 mo Tadalafil 5 mg/d 12/2016 1.061 135/75 85
93 mo Tadalafil 5 mg/d 09/2017 1.29 110/70 80
1The duplexsonography at month 84 was done with a different device.
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Table 1 shows that the PDE-5-inhibitor induced an 
increase of portal venous flow. Within a two-year 
duration this increase was verified by two independent 
methods (Doppler sonography and MRT). 
This first documented case of a long-term app-
lication of PDE-5 inhibitors in cirrhotic portal hyper-
tension could initiate the discussion about this group 
of drugs as novel adjunct therapy in this setting. 
Further clinical studies must be conducted before 
PDE-5 inhibitors can be safely recommended for this 
indication. In this patient the effect of Tadalafil on 
portal blood flow persisted for eight years. Presently, 
there is still no generally accepted non-invasive marker 
for portal pressure[19]. The quantification of liver 
hemodynamics with Doppler sonography has been 
shown to correlate with the HVPG to some degree[20,21]. 
The effect on portal blood flow may therefore be a 
further surrogate marker for the influence of a drug 
on portal pressure in portal hypertension. It can be 
supposed that an increase of portal flow induced by 
a PDE-5-inhibitor in liver cirrhosis may indicate a 
preserved reactivity of the sinusoids and lowering of 
portal pressure by the drug. However, the reliability of 
the sonographic data depends on the expertise of the 
examiner. In this case, the MRI measurement showed 
an effect consistent with the Doppler sonographic 
results. Therefore, it is probable that during the long-
term therapy with Tadalafil the positive effect on portal 
pressure persisted. 
Another notable observation was that during the 
eight years of follow-up no signs of deterioration of 
liver function were found. AIH, PBC, and AIH/PBC 
overlap syndrome have unfavourable prognosis once 
cirrhosis developed and even more after bleeding 
from esophageal varices[22-25]. This raises the question 
whether PDE-5-inhibitors could improve or stabilize the 
function in a diseased liver. In thioacetamide-induced 
liver fibrosis/cirrhosis in animals Sildenafil was shown 
to induce a reversal of liver damage and fibrosis[26], 
and Udenafil had a positive effect on degree of fibrosis 
in rats[27]. It may be speculated whether some kind 
of remodelling in a diseased liver may be induced 
by long-term administration of a PDE-5-inhibitor by 
influencing hepatic stellate cells which are suggested 
as key mediators of fibrosis[28]. In the presented case 
the diagnosis of cirrhosis had been done in 1989. 
The course of disease was relatively stable under 
immunosuppressive therapy for 20 years. However, 
episodes of upper gastrointestinal bleeding occurred. 
It is unlikely that after such a time period a spontane-
ous improvement in portal hypertension would occur. 
Echocardiographic examinations in the year 2009, 
2013 and 2017 revealed constant findings. Taken 
together with stable values of blood pressure and heart 
rate no significant changes in systemic circulation were 
detected during the years of follow-up. Therefore, 
the improvement in portal hemodynamics could be 
attributed to the application of the PDE-5-inhibitors.
In conclusion, in this case of a female patient with 
liver cirrhosis due to overlap-syndrome of AIH and 
primary biliary cholangitis the application of Vardenafil 
or Tadalafil induced a decrease of portal pressure by 
14% and 15%, respectively, and an increase of portal 
vein blood flow by 28% (Doppler sonography) and 
16% (MRT). The use of a long-acting PDE-5-inhibitor 
Figure 2  Distal aspect of the esophagus (12/2016). Endoscopy shows scarring in the distal esophagus caused by sclerosing and banding, the old varices remain 
thrombosed.
Figure 3  Computer tomographic angiography of the abdomen (09/2017). 
These sections show the normal sized-cirrhotic liver with the portal vein draining 
blood in prograde direction (solid arrow). The spleen is considerably enlarged. 
There is a collateral blood flow originating from the splenic hilus via an enlarged 
ovarian vein to the pelvis (dashed arrows).
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led to a long-lasting improvement of portal blood flow. 
During the eight years of follow-up no further bleeding 
from esophageal varices occurred.
ARTICLE HIGHLIGHTS
Case characteristics
This is the first report of long-term treatment of portal hypertension with PDE-5 
inhibitors.
Clinical diagnosis
Variceal bleeding in liver cirrhosis due to autoimmune hepatitis.
Differential diagnosis
Diagnosis of cirrhosis was done 20 years before start of treatment, so the 
decline in portal hypertension is probably attributable to PDE-5-Inhibitor-
treatment rather than spontaneous improvement.
Laboratory diagnosis
Improvement of portal hypertension was verified by invasive measurement of 
hepatovenous pressure gradient.
Imaging diagnosis
MRI and duplex sonographic images verified improvement in portal hemo-
dynamics.
Pathological diagnosis
Liver cirrhosis was histologically confirmed 20 years prior to PDE-5-Inhibitor 
treatment.
Treatment
Oral treatment with Tadalafil 5mg once daily.
Related reports
Targeting the nitric oxide (NO)-cGMP-pathway in other diseases like pulmonary 
hypertension or erectile dysfunction.
Term explanation 
Non-selective beta-blockers are the mainstay of medical therapy for portal 
hypertension in liver cirrhosis.
Experiences and lessons
Influencing the NO-pathway by the use of PDE-5 inhibitors may have long-term 
beneficial effects in compensated cirrhosis.
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